Remove 2004 Remove Healthcare Remove Healthcare Provider
article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

However, the good news is that patients are asking their doctors for help—76% of surveyed patients reported having talked with their healthcare providers about migraine treatment options, and within that group, 64% and 54% discussed acute medications and preventive treatments, respectively.

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Preparing for stricter standards on substances of human origin

European Pharmaceutical Review

Overall, while the proposed regulation on SoHO may present some challenges for ATMP developers, it is also expected to ultimately improve patient safety and thus build trust not only in ATMPs, but also among patients and healthcare providers, which could ultimately benefit ATMP developers in the long run. Cited 2023Mar].

Safety 75
article thumbnail

Uri Goren

Cadensee

02:25 Uri Goren talks about his road to become a trailblazer and advocate for patient-centric healthcare. 52:21 Uri's opinion about the main problem that needs to be solved for the healthcare market with technology. When he was going through his cancer, he died in 2004. Interview Transcription (mild edits).

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.